Balanced news tone
News Sentiment
ARTV sentiment intelligence
Artiva Biotherapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
69 relevant articles
News tone and price action are not far from neutral.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+0.3% over one week, +12.9% over four weeks, trend active, and materially above fair value.
Ra Capital Management funds buy $194k in Artiva Biotherapeutics stock By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
83/100 classification
One-week reaction
0.3%
Price digesting
Trend fit
Trend active
12.9% over four weeks
Fair value
49.6%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
26
Neutral
38
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
MT Newswires
Direct company coverage
Artiva Biotherapeutics Reports Positive AlloNK Data Across Autoimmune Diseases at EULAR 2026
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 08 Jun 2026 11:17
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 12:00
- Source
- GlobeNewswire
Quiver Quantitative
Direct company coverage
Insider Purchase: 10% owner at $ARTV Buys 347,222 Shares | ARTV Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- Quiver Quantitative
eciks.org
Direct company coverage
UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+
- Tone
- Positive 84/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- eciks.org
simplywall.st
Direct company coverage
Have Insiders Sold Artiva Biotherapeutics Shares Recently?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 07:00
- Source
- simplywall.st
GlobeNewswire
Direct company coverage
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 20:05
- Source
- GlobeNewswire
MT Newswires
Direct company coverage
Artiva Biotherapeutics Appoints Diego Miralles as President
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 12:57
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 12:00
- Source
- GlobeNewswire
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Quiver Quantitative
Direct company coverage
PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Quiver Quantitative
simplywall.st
Direct company coverage
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
MT Newswires
Direct company coverage
Wedbush Adjusts Price Target on Artiva Biotherapeutics to $40 From $23, Maintains Outperform Rating
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 08 May 2026 12:28
- Source
- MT Newswires
Stocktwits
Direct company coverage
ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Stocktwits
Seeking Alpha
Direct company coverage
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Seeking Alpha
GlobeNewswire
Direct company coverage
Artiva Biotherapeutics Announces Pricing of $300 Million
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- GlobeNewswire
Seeking Alpha
Direct company coverage
Artiva stock up on trial data for lead asset (ARTV:NASDAQ)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Seeking Alpha
GlobeNewswire
Direct company coverage
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 07:00
- Source
- GlobeNewswire
Market source
Direct company coverage
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Market source
StockStory
Direct company coverage
GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Apr 2026 07:00
- Source
- Seeking Alpha
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Market source
Direct company coverage
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Market source
Kavout | AI
Direct company coverage
Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 09:53
- Source
- Kavout | AI
TIKR.com
Direct company coverage
Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 26 Feb 2026 08:00
- Source
- TIKR.com